•Vitreous floaters may predict RD development•Outlook Therapeutics wins FDA appeal for wet AMD BLA •PECAA debuts private label 1-day contact lenses developed by CooperVision•Low vision rehab less effective in patients with hearing loss•Neuvasq highlights novel antibody approach for restoring blood-retina barrier in wet AMD and DME•Vitreous floaters may predict RD development•Outlook Therapeutics wins FDA appeal for wet AMD BLA •PECAA debuts private label 1-day contact lenses developed by CooperVision•Low vision rehab less effective in patients with hearing loss•Neuvasq highlights novel antibody approach for restoring blood-retina barrier in wet AMD and DME
HEADLINES
FEATURED
Leadership changes are underway in the eyecare space—and we’ve got the latest.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
